The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy

Springer, Jochen, Tschirner, Anika, Hartman, Kai, von Haehling, Stephan, Anker, Stefan D and Doehner, Wolfram (2013) The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. International Journal of Cardiology, 168 (4). pp. 3527-3531. ISSN 1874-1754

Full text not available from this repository.


Cachexia is a common complication of cancer and may be responsible for 22% of all cancer-related deaths. The exact cause of death in cancer cachexia patients is unknown. Recently, atrophy of the heart has been described in cancer cachexia animal models, which resulted in impaired cardiac function and is likely to contribute to mortality. In cancer patients hyperuricaemia independent of tumour lysis syndrome is often associated with a worse prognosis. Xanthine oxidase (XO) metabolizes purines to uric acid and its inhibition has been shown to improve clinical outcome in patients with chronic heart failure.

Item Type: Article
Additional Information: Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Uncontrolled Keywords: sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 24 Jan 2014 12:48
Last Modified: 06 May 2022 00:23
DOI: 10.1016/j.ijcard.2013.05.063

Actions (login required)

View Item View Item